InsiderClue

Every filing, one decision per row.

Transactions

One row for every decision an insider filed. Open-market buying and selling only. Vesting, grants and the shares withheld to pay the tax on them are not decisions.

Views

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

Create an account Sign in
Companies 1/25
KROS
Result 25 decisions over 120 months
Reset filters
Direction ?
Both25 Bought11 Sold14
Sort by ?
Most recent Largest amount Share of holding
Window ?
1 mo 12 mo 120 mo
Plan ?
Any Discretionary Scheduled (10b5-1) Not stated
Minimum amount ?
Any $100K $1M $10M $100M $500M
Share of their own holding ?
What the chief executive holds ?
Company: KROS Minimum: $1M
Company
Date
Insider
Role
Action ?
Shares
Amount
Of holding
KROS Keros Therapeutics, Inc.
15 Oct 2025
ADAR1 Capital Management, LLC
10% owner indirect
Sold at will 3×
5,389,264
$95.66M
100%
KROS Keros Therapeutics, Inc.
15 Oct 2025
Pontifax Management 4 G.P. (2015) Ltd.
10% owner indirect
Sold at will 4×
4,787,331
$84.98M
100%
KROS Keros Therapeutics, Inc.
9 Apr 2025
ADAR1 Capital Management, LLC
10% owner indirect
Bought 5×
934,258
$9.46M
27.0%
KROS Keros Therapeutics, Inc.
13 Aug 2024
ORBIMED ADVISORS LLC
Director indirect
Sold at will 2×
250,000
$11.00M
67.7%
KROS Keros Therapeutics, Inc.
13 Aug 2024
GORDON CARL L
Director indirect
Sold at will 2×
250,000
$11.00M
67.7%
KROS Keros Therapeutics, Inc.
4 Nov 2023
Regnante Keith
Chief Financial Officer
Sold at will
40,000
$1.81M
100%
KROS Keros Therapeutics, Inc.
15 Jul 2022
Lachey Jennifer
Chief Scientific Officer
Sold, plan not stated
46,034
$1.38M
32.6%
KROS Keros Therapeutics, Inc.
4 Jan 2022
Knowles Julius
Director indirect
Sold, plan not stated 10×
20,062
$1.15M
7.9%
KROS Keros Therapeutics, Inc.
3 Jan 2022
Knowles Julius
Director indirect
Sold, plan not stated 8×
23,555
$1.37M
8.9%
KROS Keros Therapeutics, Inc.
2 Dec 2021
Knowles Julius
Director indirect
Sold, plan not stated 8×
25,338
$1.36M
9.2%
KROS Keros Therapeutics, Inc.
1 Dec 2021
Knowles Julius
Director indirect
Sold, plan not stated 8×
22,313
$1.22M
7.9%
KROS Keros Therapeutics, Inc.
1 Nov 2021
Knowles Julius
Director indirect
Sold, plan not stated 4×
23,803
$1.00M
7.8%
KROS Keros Therapeutics, Inc.
27 Sep 2021
Knowles Julius
Director indirect
Sold, plan not stated 6×
95,302
$3.92M
23.6%
KROS Keros Therapeutics, Inc.
3 May 2021
Knowles Julius
Director indirect
Sold, plan not stated 10×
44,816
$2.58M
10.4%
KROS Keros Therapeutics, Inc.
5 Apr 2021
Knowles Julius
Director indirect
Sold, plan not stated 6×
27,151
$1.63M
6.3%
KROS Keros Therapeutics, Inc.
17 Nov 2020
Pontifax Management 4 G.P. (2015) Ltd.
10% owner indirect
Bought 4×
60,000
$3.00M
2.7%
KROS Keros Therapeutics, Inc.
17 Nov 2020
Kariv Tomer
Director indirect
Bought 4×
60,000
$3.00M
2.7%
KROS Keros Therapeutics, Inc.
17 Nov 2020
Nussbaum Ran
Director indirect
Bought 4×
60,000
$3.00M
2.7%
KROS Keros Therapeutics, Inc.
13 Apr 2020
Kariv Tomer
Director indirect
Bought 4×
437,499
$7.00M
24.0%
KROS Keros Therapeutics, Inc.
13 Apr 2020
Nussbaum Ran
Director indirect
Bought 4×
437,499
$7.00M
24.0%
KROS Keros Therapeutics, Inc.
13 Apr 2020
Pontifax Management 4 G.P. (2015) Ltd.
10% owner indirect
Bought 4×
437,499
$7.00M
24.0%
KROS Keros Therapeutics, Inc.
13 Apr 2020
GORDON CARL L
Director indirect
Bought
375,200
$6.00M
50.4%
KROS Keros Therapeutics, Inc.
13 Apr 2020
ORBIMED ADVISORS LLC
Director indirect
Bought
375,200
$6.00M
50.4%
KROS Keros Therapeutics, Inc.
13 Apr 2020
Arkin Bio Ventures Limited Partnership
10% owner
Bought
120,000
$1.92M
6.3%
KROS Keros Therapeutics, Inc.
13 Apr 2020
Lazarus Alon
Director indirect
Bought
120,000
$1.92M
6.3%
Showing 1–25 of 25.